Search

CombinatoRx™

Combination Screening

It is widely accepted that the biological pathways fundamental in many serious diseases are highly complex with individual cell types containing a unique network of pathways, and so monotherapies are often insufficient.

Combination therapies are now emerging as the standard of care1,2,3,4 in indications such as cancer, inflammation, diabetes, and infectious disease. Unfortunately, the current approach of developing combination therapies at the clinical stage misses the opportunity to identify novel multi-target mechanisms that better address the systems biology of disease and the emergence of resistance.

Learn how combination studies can benefit your drug discovery program.

Chalice™ Bioinformatics Software

Horizon’s proprietary CombinatoRx (CRx) platform and Chalice™ software provide a way to quantitatively assess how drugs or other probes of biological targets interact with diverse genetic backgrounds using whole-cell based phenotypic screening. The platform provides a high-throughput capability to identify synergistic or antagonistic interactions between small-molecule drugs, therapeutic antibodies or proteins that can be developed as therapeutic candidates.

Try Chalice™ Online

Get the Full Version of Chalice™

Access Chalice user manual online or Download as a PDF
Order CombinatoRx™ Products and Services:

For more information and to contact us simply click below

Order Products and Services

Alternatively for more information contact us at info@horizondiscovery.com

References:

1 Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology 27:659-66.

2 Kummar, S., Chen, H.X., Wright, J., Holbeck, S., Millin, M.D., Tomaszewski, J., Zweibel, J., Collins, J. and Doroshow, J.H. (2010) Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nature Review Drug Discovery 9:843-855.

3 Woodcock, J., Griffin, J.P. and Behrman, R.E. (2011) Development of novel combination therapies. N Engl J Med 364:985-987 

4 Al-Lazikani, B., Banerji,U. and Workman, P.. (2012) Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology 30:7, 679-692

×
×
×
×
×
×
×
×
×
×
×
×
×
×
×
×
×
×
×
×

Login Error


There was an error with your login - please try again.

Forgotten your password? Click here

OK ×

Recover your password

Please enter your email address and we'll send you a reset link

×

Thank you.


We've sent you an email to reset your password.

OK ×

Add Voucher


Sorry, Unable to add voucher

OK ×

Account Error


There was an error updating your details.

OK ×

Thank you.


Your changes have been saved.

OK ×

Thank you


Thank you for registering to the Horizon Discovery website. We hope you enjoy and benefit from our online resources, and please feel free to contact us if you have any queries or feedback through the website itself or at info@horizondiscovery.com.


Got a few seconds to tell us what you're interested in?



Tick all that apply:

Horizon’s Offerings

Application Area

Disease Area

 

Other Disease Area (Please specify)


OK
×

Thank you.


Items have been saved to your basket.

OK ×